Pasithea therapeutics reports positive pharmacodynamic results demonstrating robust target engagement from its ongoing phase 1 clinical trial of pas-004

Pasithea tx' pas-004 shows up to 91% perk inhibition in phase 1 trial; one pancreatic cancer patient sees 4+ months stable disease and tumor shrinkage.

KTTA Ratings Summary

KTTA Quant Ranking